ArticleMalaria journal2025
Therapeutic efficacy of artemether-lumefantrine in North-Eastern states of India and prevalence of drug resistance-associated molecular markers.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPlasmodium falciparum is the main cause of malaria in North-Eastern (NE) states of India. Artemether-lumefantrine (AL) was introduced as first-line therapy against uncomplicated P. falciparum cases in 2013 after the emergence of resistance to sulfadoxine-pyrimethamine. The aim of the study was to assess the therapeutic efficacy of AL and status of molecular markers in the circulating parasites.
methodsTherapeutic efficacy of AL was assessed in NE states as per World Health Organization guidelines. Patients with P. falciparum positive peripheral blood smear were enrolled and treated with AL and clinical and parasitological parameters were monitored over a 28-day follow-up period. Furthermore, the pfmdr1, pfdhfr, pfdhps and pfk13 genes were amplified and sequenced for mutation analysis.
resultsA total of 231 cases were enrolled and therapeutic efficacy was determined in 215 (93.1%) patients who completed their 28 days' follow-up while 10 patients withdrew and 6 were lost to follow up during study. Overall 99.5% and 98.6% of adequate clinical and parasitological response was observed with and without PCR correction, respectively. Only three cases (1.4%) of late parasitological failure were observed in Mizoram site. One case of recrudescence and two cases of reinfection were detected by msp1 and msp2 genotyping. Mutation analysis showed the 15.8%, 100%, 90.5% mutants in pfmdr1, pfdhfr and pfdhps gene respectively and three non-synonymous mutations were also found in pfk13gene.
conclusionsThis study reports that AL is efficacious against uncomplicated P. falciparum cases in NE states of India. However, prevalence of mutations in molecular marker associated with anti-malarial resistance (pfmdr1, pfdhfr, pfdhps and pfk13) gene indicate possible emergence of drug resistance. This is to underline the fact that the drug is efficacious for now, but rising mutations indicate that continuous monitoring is essential for effective treatment regime.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.